Since the discovery that the ACE1/Ang II/AT1R axis is responsible for the injurious effects of the brain and systemic RAS, and is involved, besides other factors, in the development of AD [47], blocking this axis by various pharmacological agents has become a topic of interest for researchers. The gene discussed is AGTR1; the disease is Alzheimer disease.